Jeffrey Lawrence Schwartz - 08 Sep 2026 Form 4 Insider Report for KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: KMTS
Reported as of: 08 Sep 2026
Net transaction value: -$97,942
SEC form: 4
Accepted by SEC: 10 Sep 2026, 20:43:30 UTC
Prior SEC filing: 08 Sep 2025
Source filing: View source filing
Reporting owner signature: /s/ Jeffrey Schwartz

Key filing fact

Jeffrey Lawrence Schwartz filed Form 4 for KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) on 10 Sep 2026.

Key facts

This page summarizes Jeffrey Lawrence Schwartz's Form 4 filing for KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 10 Sep 2026, 20:43.

Change

Previous filing in this sequence was filed on 08 Sep 2025.
Current net transaction value: -$97,942.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001702957 Primary reporting owner

Schwartz Jeffrey Lawrence

Relationship: Director, 10%+ Owner
Address: C/O BAIN CAPITAL INVESTORS, LLC, 200 CLARENDON STREET, BOSTON
Signature: /s/ Jeffrey Schwartz
Signature date: 10 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KMTS transaction

Common Shares

Sale

Transaction value: $97,942
Shares: -3,890
Change %: -36%
Price: $25.18
Shares after: 7,019
Date: 08 Sep 2026
Ownership: Direct
Footnotes: F1, F2

KMTS transaction

Common Shares

Award

Transaction value
Shares: +7,217
Change %: +103%
Price
Shares after: 14,236
Date: 09 Sep 2026
Ownership: Direct
Footnotes: F3

KMTS holding

Common Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 25,172,338
Date: 08 Sep 2026
Ownership: See footnote
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

The sale reported in this Form 4 represents a nondiscretionary sale of shares required to be sold by the reporting person pursuant to sell to cover transactions to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units.

Footnote F2

The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $24.9100 to $25.4240. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

Footnote F3

The reported securities represent restricted stock units ("RSUs") which each entitle the Reporting Person to receive one common share of the Issuer. The RSUs will vest on September 9, 2027, subject to the Reporting Person's continued service through such date.

Footnote F4

Represents 25,172,338 common shares of the Issuer held directly by Bain Charger Holdings, L.P. ("Bain Charger"). Mr. Schwartz is a Partner of Bain Capital Investors, LLC, which is the general partner of Bain Charger. As a result, Mr. Schwartz may be deemed to share voting and dispositive power with respect to the securities held by Bain Charger. Mr. Schwartz disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.